Second, the inclusion of genetic data for future studies could facilitate testing our aforementioned hypothesis that TREM2 signaling may enact disease‐associated microglia for detrimental/beneficial factors interacting with the manifestation of systemic symptomatology in a portion of non‐CNS cancer survivors. This evidence concerns the gene TREM2 and central nervous system cancer.